National Hemophilia Foundation
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of National Hemophilia Foundation
Names of Lobbyists
Most Frequently Disclosed Lobbying Issues
- Fed Budget & Appropriations,
- Medical Research & Clin Labs,
- Medicare & Medicaid,
Most Frequently Disclosed Bills
Bill No. Title H.R.1919 Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2011 S.3295 Department of Labor Appropriations Act, 2013 H.R.3070 Department of Education Appropriations Act, 2012 S.1599 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012 S.3187 Food and Drug Administration Safety and Innovation Act
RegulationsMentioned in 7 dockets; Submitted to 1 docket
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "National Hemophilia Foundation" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for National Hemophilia Foundation
Mentions in Document Text
View all mentions data for National Hemophilia Foundation
- Toggle 2 HHS Establishment of Exchanges and Qualified Health Plans 2011
- Toggle 2 CMS Exchanges Part II--Standards Related to Essential Health Benefits; Health Insurance Issuer and Exchange Responsibilities with Respect to Actuarial Value, Quality, and Accreditation CMS-9980-P 2012
- Toggle 1 FDA Applications for Food and Drug Administration Approval to Market a New Drug; Revision of Postmarketing Reporting Requirements--Discontinuance 2011
- Toggle 1 FDA PDUFA V Patient-Focused Drug Development; Public Meeting and Request for Comments 2012
- Toggle 1 FDA Draft Guidances Relating to the Development of Biosimilar Products; Public Hearing; Request for Comments 2011
- Toggle 1 HHS Design of a Pilot Study to Assess Alternative Blood Donor Deferral Criteria for Men Who Have Had Sex with Other Men (MSM) 2012
- Toggle 1 FDA Draft Guidance for Industry: Amendment (revisions to labeling recommendations for potential risk of vCJD) to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products,” Availability 2012